8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

^{______________}

FORM 8-K

^{______________}

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 18, 2009

^{______________}

Stellar Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

^{______________}

Ontario, Canada	0-31198	Not Applicable
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

544 Egerton Street, London, Ontario, Canada, N5W 3Z8

(Address of Principal Executive Office) (Zip Code)

(519) 434-1540

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01

Regulation FD Disclosure

See Exhibit 99.1

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description
99.1	Stellar Pharmaceuticals Announces the Launch of Neovisc® Single Dose

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

STELLAR PHARMACEUTICALS INC.
By:	/s/ PETER RIEHL
	Peter Riehl President and Chief Executive Officer

Date:  June 18, 2009

EX-99.1

EXHIBIT 99.1

Press Release Source: Stellar Pharmaceuticals Inc.

STELLAR PHARMACEUTICALS ANNOUNCES THE LAUNCH OF NEOVISC^® SINGLE DOSE

LONDON, ONTARIO - June 18, 2009 - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCBB:SLXCF.OB), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced at their annual shareholders meeting held on June 17, the launch of NeoVisc^® Single Dose in the Canadian market.

Peter Riehl, Stellar’s President & CEO, stated, “The osteoarthritis market is an extremely large market, currently affecting about 10% of the global population.  As our population continues to age, the prevalence of osteoarthritis will also grow providing tremendous opportunity for products such as NeoVisc.  The Company is pleased to be able to offer the convenience of NeoVisc Single Dose, as a single injection alternative, to physicians and their patients.  Although the relief period on the single dose may not be as long as the current 3 dose NeoVisc treatment, the Company felt is was important to respond to market demand for convenience and yet maintain an affordable alternative.”

Stellar is currently the only company across Canada to provide a natural linear molecular hyaluronate product in both a single and three injectable dose format.

About NeoVisc®

NeoVisc is a viscosupplement that when injected into the effected joints, offers patients a drug-free method to treat the pain of osteoarthritis ("OA"). NeoVisc is available in Canada, Europe, Asia, Middle East and the Caribbean as a three injection product administered over a two-week period.  The 3 dose NeoVisc has been shown to provide symptomatic relief of OA pain for an average of 6-12 months.  There are certain situations however, where administering the 3 dose treatment is difficult to schedule for certain patients in a busy practice.  NeoVisc Single Dose provides physicians and patients the convenience of a single injection treatment.  This single injection provides symptomatic relief but usually over a shorter duration than the 3 dose NeoVisc.  Both the NeoVisc Single Dose and 3 dose NeoVisc use a natural, linear hyaluronan derived from a fermentation process, unlike competitors that use an altered, cro ss-linked hyaluronan.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst® its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

For more information contact:

Stellar Pharmaceuticals Inc.                   

-OR-

Arnold Tenney, Chairman

Peter Riehl, President & CEO

(416) 587-3200

(519) 434-1540

email – corpinfo@stellarpharma.com